BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23991948)

  • 1. LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer.
    Han D; Li SJ; Zhu YT; Liu L; Li MX
    Asian Pac J Cancer Prev; 2013; 14(7):4033-9. PubMed ID: 23991948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor.
    Gao Y; Ge G; Ji H
    Protein Cell; 2011 Feb; 2(2):99-107. PubMed ID: 21380642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting LKB1 in cancer - exposing and exploiting vulnerabilities.
    Momcilovic M; Shackelford DB
    Br J Cancer; 2015 Aug; 113(4):574-84. PubMed ID: 26196184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LKB1 Tumor Suppressor: Therapeutic Opportunities Knock when LKB1 Is Inactivated.
    Zhou W; Zhang J; Marcus AI
    Genes Dis; 2014 Sep; 1(1):64-74. PubMed ID: 25679014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the Lkb1/AMPK pathway in hematopoietic stem cells and Leukemia.
    Saito Y; Nakada D
    Crit Rev Oncog; 2014; 19(5):383-97. PubMed ID: 25404152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the LKB1 tumor suppressor.
    Zhao RX; Xu ZX
    Curr Drug Targets; 2014 Jan; 15(1):32-52. PubMed ID: 24387336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
    Groenendijk FH; Mellema WW; van der Burg E; Schut E; Hauptmann M; Horlings HM; Willems SM; van den Heuvel MM; Jonkers J; Smit EF; Bernards R
    Int J Cancer; 2015 Mar; 136(6):1434-44. PubMed ID: 25080865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress on liver kinase B1 (LKB1): expression, regulation, downstream signaling and cancer suppressive function.
    Gan RY; Li HB
    Int J Mol Sci; 2014 Sep; 15(9):16698-718. PubMed ID: 25244018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response.
    Li F; Han X; Li F; Wang R; Wang H; Gao Y; Wang X; Fang Z; Zhang W; Yao S; Tong X; Wang Y; Feng Y; Sun Y; Li Y; Wong KK; Zhai Q; Chen H; Ji H
    Cancer Cell; 2015 May; 27(5):698-711. PubMed ID: 25936644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53.
    Co NN; Iglesias D; Celestino J; Kwan SY; Mok SC; Schmandt R; Lu KH
    Cancer; 2014 Nov; 120(22):3457-68. PubMed ID: 25042259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR.
    Richer AL; Friel JM; Carson VM; Inge LJ; Whitsett TG
    Pharmgenomics Pers Med; 2015; 8():63-79. PubMed ID: 25897257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel direct AMPK activator suppresses non-small cell lung cancer through inhibition of lipid metabolism.
    Chen X; Xie C; Fan XX; Jiang ZB; Wong VK; Xu JH; Yao XJ; Liu L; Leung EL
    Oncotarget; 2017 Nov; 8(56):96089-96102. PubMed ID: 29221189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buformin exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells.
    Kilgore J; Jackson AL; Clark LH; Guo H; Zhang L; Jones HM; Gilliam TP; Gehrig PA; Zhou C; Bae-Jump VL
    Am J Transl Res; 2016; 8(6):2705-15. PubMed ID: 27398153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression.
    Xu C; Fillmore CM; Koyama S; Wu H; Zhao Y; Chen Z; Herter-Sprie GS; Akbay EA; Tchaicha JH; Altabef A; Reibel JB; Walton Z; Ji H; Watanabe H; Jänne PA; Castrillon DH; Rustgi AK; Bass AJ; Freeman GJ; Padera RF; Dranoff G; Hammerman PS; Kim CF; Wong KK
    Cancer Cell; 2014 May; 25(5):590-604. PubMed ID: 24794706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator.
    Faubert B; Vincent EE; Poffenberger MC; Jones RG
    Cancer Lett; 2015 Jan; 356(2 Pt A):165-70. PubMed ID: 24486219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway.
    Sanli T; Steinberg GR; Singh G; Tsakiridis T
    Cancer Biol Ther; 2014 Feb; 15(2):156-69. PubMed ID: 24100703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unravelling the connection between metabolism and tumorigenesis through studies of the liver kinase B1 tumour suppressor.
    Shackelford DB
    J Carcinog; 2013 Aug; 12():16. PubMed ID: 24082825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR signaling in tumorigenesis.
    Xu K; Liu P; Wei W
    Biochim Biophys Acta; 2014 Dec; 1846(2):638-54. PubMed ID: 25450580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor suppression and promotion by autophagy.
    Ávalos Y; Canales J; Bravo-Sagua R; Criollo A; Lavandero S; Quest AF
    Biomed Res Int; 2014; 2014():603980. PubMed ID: 25328887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
    Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.